5-BDBD是一种有效的选择性P2X4受体拮抗剂，IC50值为0.5-0.75µM，能够抑制rP2X4R介导的电流。
Cas No.:768404-03-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
5-BDBD is a potent and selective P2X4 receptor antagonist with an IC50 value of 0.5-0.75µM, capable of inhibiting rP2X4R-mediated currents[1-2]. 5-BDBD can alleviate asthma symptoms and has potential for treating alcoholic fatty liver disease[3-4].
In vitro, treatment of prostate cancer cells (DU145 cells) with 5-BDBD (5 or 10µM) for 24 to 72 hours significantly inhibited their migration and invasion capabilities and induced the expression of the apoptosis marker cleaved caspase-3[5]. Treatment of primary rat osteoblasts with 5-BDBD (0.1-10µM) for 14 days dose-dependently inhibited bone nodule formation and reduced alkaline phosphatase activity[6].
In vivo, continuous administration of 5-BDBD (1.0mM; via an implanted osmotic pump at a flow rate of 1.0µL/h for 3 days) to adult male Sprague-Dawley rats subjected to cortical contusion injury (CCI) significantly suppressed the activation of microglia in the ipsilateral cortex and hippocampus and reduced Iba-1 protein expression levels. 5-BDBD also significantly decreased the levels of pro-inflammatory cytokines in the ipsilateral cortex and hippocampus[7]. Treatment of 8-12-week-old wild-type mice subjected to 60 minutes of middle cerebral artery occlusion (MCAo) with 5-BDBD (1mg/kg; administered orally daily for 3 days) significantly reduced infarct volume and neurological deficit scores at 3 days after stroke, and decreased the levels of the pro-inflammatory cytokine IL-1β and blood-brain barrier permeability[8].
References:
[1] Long T, He W, Pan Q, et al. Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation. J Neuroinflammation. 2018 Aug 30;15(1):245.
[2] Coddou C, Sandoval R, Hevia MJ, et al. Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor. Neurosci Lett. 2019 Jan 18;690:219-224.
[3] Hu B, Feng X, Wang L, et al. 5-BDBD ameliorates an OVA-induced allergic asthma by the reduction of Th2 cytokines production. Iran J Basic Med Sci. 2018 Apr;21(4):364-369.
[4] Xia GQ, Cai JN, Wu X, et al. The mechanism by which ATP regulates alcoholic steatohepatitis through P2X4 and CD39. Eur J Pharmacol. 2022 Feb 5;916:174729.
[5] Maynard JP, Lu J, Vidal I, et al. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol. 2022 Feb;256(2):149-163.
[6] Orriss IR, Davies BK, Bourne LE, et al. Modulation of osteoblast differentiation and function by the P2X4 receptor. Purinergic Signal. 2023 Jun;19(2):367-378.
[7] Kobayashi M, Moro N, Yoshino A, et al. Inhibition of P2X4 and P2X7 receptors improves histological and behavioral outcomes after experimental traumatic brain injury in rats. Exp Ther Med. 2023 Jun 23;26(2):378.
[8] Srivastava P, Cronin CG, Scranton VL, et al. Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke. Exp Neurol. 2020 Jul;329:113308.
5-BDBD是一种有效的选择性P2X4受体拮抗剂，IC50值为0.5-0.75µM，能够抑制rP2X4R介导的电流[1-2]。5-BDBD能够缓解哮喘症状，且具有治疗酒精性脂肪肝的潜力[3-4]。
在体外，5-BDBD（5或10μM）处理前列腺癌细胞（DU145细胞）24至72小时，显著抑制其迁移和侵袭能力，并诱导凋亡标志物cleaved caspase-3的表达[5]。5-BDBD（0.1-10μM）处理原代大鼠成骨细胞14天，剂量依赖性地抑制骨结节形，并降低碱性磷酸酶活性[6]。
在体内，5-BDBD（1.0mM；通过植入的渗透泵以1.0μL/h流速连续给药3天）处理遭受皮质挫伤（CCI）的成年雄性Sprague-Dawley大鼠，显著抑制损伤同侧皮层和海马区小胶质细胞的激活，并降低Iba-1蛋白表达水平，还显著降低损伤同侧皮层和海马区促炎细胞因子的水平[7]。5-BDBD（1mg/kg；每日口服；持续3天）处理经历60分钟大脑中动脉闭塞（MCAo）的8-12周龄野生型小鼠，在卒中后3天显著降低梗死体积和神经功能缺损评分，并减少促炎细胞因子IL-1β的水平和血脑屏障通透性[8]。
| Cell experiment [1]: | |
Cell lines | DU145 cells (human prostate cancer cell line) |
Preparation Method | DU145 cells were maintained in MEM supplemented with 10% fetal bovine serum (FBS). Cells were treated with 5-BDBD at concentrations of 5 or 10µM for 24-72 hours. |
Reaction Conditions | 5 or 10µM; 24-72 hours. |
Applications | 5-BDBD treatment significantly decreased DU145 cell viability and migration. |
| Animal experiment [2]: | |
Animal models | 8-12-week-old male and female wild-type C57B/6 mice. |
Preparation Method | Mice were subjected to a 60-minute right middle cerebral artery occlusion (MCAo) followed by reperfusion. The P2X4R antagonist 5-BDBD (1mg/kg) or vehicle (0.5% methyl cellulose) was administered orally (P.O.) daily for 3 days, starting 4 hours after MCAo. |
Dosage form | 1mg/kg; P.O.; Daily for 3 days. |
Applications | 5-BDBD treatment significantly reduced infarct volume and neurological deficit (ND) score at 3 days after stroke. 5-BDBD also significantly reduced mortality by day 30 after stroke. |
References: | |
| Cas No. | 768404-03-1 | SDF | |
| 化学名 | 5-(3-bromophenyl)-1H-benzofuro[3,2-e][1,4]diazepin-2(3H)-one | ||
| Canonical SMILES | BrC1=CC(C2=NCC(NC3=C2OC4=CC=CC=C34)=O)=CC=C1 | ||
| 分子式 | C17H11BrN2O2 | 分子量 | 355.19 |
| 溶解度 | <35.52mg/ml in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8154 mL | 14.077 mL | 28.1539 mL |
| 5 mM | 563.1 μL | 2.8154 mL | 5.6308 mL |
| 10 mM | 281.5 μL | 1.4077 mL | 2.8154 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet